Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
輝瑞（Pfizer，NYSE:PFE）週二發佈了第二季度調整後的每股收益報告，爲0.60美元，同比下降11％，超過了0.46美元的共識預期。
The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
這家美國製藥公司報告了132.8億美元的銷售額，同比增長2％（運營上增長3％），超過了130.2億美元的共識預期。增長主要是由於我們的多個收購產品，主要在市場內的產品以及最近的商業推出的增長貢獻，這些增長彌補了Comirnaty預期下降的影響。
Truist Securities sees the strong demand growth as highly encouraging and, at current levels, Pfizer shares are very attractive given the company's diverse portfolio that is gaining momentum, effective cost-cutting initiatives, and a commitment to maintaining or growing an attractive dividend.
Truist證券認爲需求增長強勁非常令人鼓舞，考慮到該公司不斷增強的多樣化投資組合、有效的成本削減措施以及維持或增長可觀分紅的承諾，在當前水平下，輝瑞股票非常具有吸引力。
The analyst maintains the Buy rating, with a price target of $36.
分析師保持買入評級，並將價格目標定爲36美元。
Goldman Sachs notes that Pfizer's performance included noteworthy standouts (Vyndaqel, Nurtec) and evidence that integration of the Seagen acquisition is progressing well.
高盛指出，輝瑞的業績表現包括值得一提的亮點（Vyndaqel、Nurtec）以及Seagen收購整合順利的證據。
Goldman Sachs analyst writes, "We were struck by the raised COVID-19 guidance, as we interpret the decision as being underpinned by confidence. Gross margin gains provide reassurance relative to concerns earlier in the year, as gains from cost realignment initiatives are materializing."
高盛分析師寫道：“我們對提高的COVID-19指導方針印象深刻，我們認爲這一決定是基於信心作出的。毛利率的增長提供了一定的保障，從成本重新調整措施中獲得的收益正在實現，相對於年初的擔憂變得有所緩解。”
The analyst keeps the Buy rating and raises the price target from $31 to $34.
分析師保持買入評級，並將價格目標從31美元上調至34美元。
BMO Capital Markets writes Pfizer's (Outperform, $36 target) second-quarter earnings highlight the direction of the business as it moves out of the shadow of COVID.
BMO資本市場指出，輝瑞（跑贏市場，目標價36美元）第二季度的盈利強調了業務從COVID陰影中走出的方向。
With COVID revenue stabilizing, base revenue expanding, and clinical development focused on accelerating danuglipron in any way possible, BMO Capital analyst writes that the business's priorities are aligned with shareholders.
隨着COVID收入穩定、基礎收入擴大，以及臨床開發專注於盡可能加速danuglipron的研發，BMO Capital分析師寫道，該業務的優先事項與股東的利益保持一致。
Cantor Fitzgerald notes that concerns about Pfizer's patent cliff and downside risk to COVID-19 sales will be offset by Seagen, new product launches, and M&A expected to resume beyond 2025.
康泰菲茲傑拉爾德指出，關於輝瑞的專利懸崖和COVID-19銷售下行風險的擔憂將被Seagen、新產品推出和2025年後預計恢復的併購所抵消。
Also, along with the strong execution of its cost reduction programs, the updates could drive EPS to $3+ in 2025+ and the stock toward its price target of $45. Maintains the Overweight rating.
此外，伴隨着其成本削減計劃的強有力的執行，最新信息預計可推動每股收益在2025年達到3美元以上，並推動股價走向45美元的目標。維持超配評級。
Price Action: PFE stock is down 1.85% at $30.81 at last check Wednesday.
價格行動：PFE股票在週三最後一次檢查時下跌1.85％，報30.81美元。
Photo via Shutterstock
圖片來自shutterstock。
- One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program.
- 一年五次試驗失敗：FibroGen終止胰腺癌治療計劃。